Comparative Pharmacology
Head-to-head clinical analysis: DRONABINOL versus SYNDROS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONABINOL versus SYNDROS.
DRONABINOL vs SYNDROS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at cannabinoid receptors CB1 and CB2; mimics endogenous cannabinoids, inhibiting adenylate cyclase and modulating neurotransmitter release (e.g., GABA, glutamate).
Dronabinol is a cannabinoid receptor type 1 (CB1) agonist, activating CB1 receptors in the central nervous system to inhibit emetic signals and stimulate appetite. It also has partial agonist activity at cannabinoid receptor type 2 (CB2).
2.5-10 mg orally twice daily, titrated to effect; maximum 15 mg per day in divided doses.
5 mg/m² orally 1-3 hours before chemotherapy, initially; may increase by 2.5 mg/m² increments as tolerated, maximum 15 mg/m² per dose.
None Documented
None Documented
Clinical Note
moderateDronabinol + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Dronabinol."
Clinical Note
moderateDronabinol + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Dronabinol."
Clinical Note
moderateDronabinol + Cyclosporine
"The serum concentration of Cyclosporine can be increased when it is combined with Dronabinol."
Clinical Note
moderateDronabinol + Fluconazole
Terminal elimination half-life is approximately 25–36 hours in chronic users due to extensive tissue distribution and slow release from fat stores; in naive users, half-life is shorter, around 20–30 hours. The prolonged half-life contributes to accumulation with repeated dosing.
Terminal elimination half-life is 28–61 hours (mean ~32 hours) in adults; prolonged with high-fat meal. Clinical context: Steady state achieved in 5–6 days.
Primarily hepatic metabolism followed by biliary and fecal excretion. Approximately 65% eliminated in feces and 35% in urine, mostly as metabolites. Less than 5% of unchanged drug is excreted in urine.
Approximately 65% of a dose is excreted in feces (primarily as hydroxylated and carboxylated metabolites) and 35% in urine (as metabolites, with <5% unchanged drug).
Category D/X
Category C
Cannabinoid
Cannabinoid
"The serum concentration of Fluconazole can be increased when it is combined with Dronabinol."